SPECIALTY GUIDELINE MANAGEMENT

POMALYST (pomalidomide)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Treatment of multiple myeloma, in combination with dexamethasone, in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of their last therapy

B. Compendial Uses

- 1. Systemic light chain amyloidosis
- 2. AIDS-related Kaposi sarcoma

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

A. Multiple myeloma

Authorization of 12 months may be granted for the treatment of multiple myeloma when the member has previously received at least two prior therapies for multiple myeloma.

B. Systemic light chain amyloidosis

Authorization of 12 months may be granted for the treatment of systemic light chain amyloidosis.

C. AIDS-Related Kaposi Sarcoma

Authorization of 12 months may be granted for the treatment of AIDS-related Kaposi sarcoma.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCES

- 1. Pomalyst [package insert]. Summit, NJ: Celgene Corporation; May 2018.
- 2. The NCCN Drugs & Biologics Compendium[®] © 2018 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed September 13, 2018.
- 3. The NCCN Clinical Practice Guidelines in Oncology® Multiple Myeloma (Version 1.2019) © 2018 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed October 4, 2018.
- 4. The NCCN Clinical Practice Guidelines in Oncology® Systemic Light Chain Amyloidosis (Version 1.2018)

Pomalyst 2234-A SGM P2018

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



2234-A

- © 2018 National Comprehensive Cancer Network, Inc. Available at: www.nccn.org. Accessed October 4, 2018.
- The NCCN Clinical Practice Guidelines in Oncology® AIDS-Related Kaposi Sarcoma (Version 1.2018) © 2018 National Comprehensive Cancer Network, Inc. Available at: www.nccn.org. Accessed October 4, 2018.

Pomalyst 2234-A SGM P2018

© 2019 CVS Caremark. All rights reserved.



pharmaceutical manufacturers that are not affiliated with CVS Caremark.

permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of